WO1995005853A1 - Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides - Google Patents
Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides Download PDFInfo
- Publication number
- WO1995005853A1 WO1995005853A1 PCT/US1994/009661 US9409661W WO9505853A1 WO 1995005853 A1 WO1995005853 A1 WO 1995005853A1 US 9409661 W US9409661 W US 9409661W WO 9505853 A1 WO9505853 A1 WO 9505853A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- naked
- host
- polynucleotides
- naked polynucleotide
- polynucleotide
- Prior art date
Links
- 239000002157 polynucleotide Substances 0.000 title claims abstract description 205
- 102000040430 polynucleotide Human genes 0.000 title claims abstract description 205
- 108091033319 polynucleotide Proteins 0.000 title claims abstract description 205
- 238000000034 method Methods 0.000 title claims abstract description 86
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 84
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 22
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 18
- 241000124008 Mammalia Species 0.000 claims abstract description 7
- 230000000979 retarding effect Effects 0.000 claims abstract 2
- 108091007433 antigens Proteins 0.000 claims description 59
- 239000000427 antigen Substances 0.000 claims description 58
- 102000036639 antigens Human genes 0.000 claims description 58
- 210000001519 tissue Anatomy 0.000 claims description 57
- 108010002350 Interleukin-2 Proteins 0.000 claims description 55
- 102000000588 Interleukin-2 Human genes 0.000 claims description 53
- 108020004414 DNA Proteins 0.000 claims description 52
- 210000003491 skin Anatomy 0.000 claims description 39
- 108090000695 Cytokines Proteins 0.000 claims description 36
- 230000028993 immune response Effects 0.000 claims description 35
- 239000002299 complementary DNA Substances 0.000 claims description 33
- 230000004044 response Effects 0.000 claims description 29
- 102000004127 Cytokines Human genes 0.000 claims description 27
- 210000004877 mucosa Anatomy 0.000 claims description 26
- 230000000692 anti-sense effect Effects 0.000 claims description 22
- 102000004190 Enzymes Human genes 0.000 claims description 18
- 108090000790 Enzymes Proteins 0.000 claims description 18
- 230000005540 biological transmission Effects 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 230000002163 immunogen Effects 0.000 claims description 16
- 230000032683 aging Effects 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 238000001727 in vivo Methods 0.000 claims description 14
- 229940124532 absorption promoter Drugs 0.000 claims description 11
- 239000002561 chemical irritant Substances 0.000 claims description 11
- 239000002085 irritant Substances 0.000 claims description 11
- 231100000021 irritant Toxicity 0.000 claims description 11
- 230000001939 inductive effect Effects 0.000 claims description 10
- 230000009885 systemic effect Effects 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 8
- 210000002615 epidermis Anatomy 0.000 claims description 8
- 238000010521 absorption reaction Methods 0.000 claims description 7
- 230000004071 biological effect Effects 0.000 claims description 7
- 230000001530 keratinolytic effect Effects 0.000 claims description 7
- -1 antibodies Proteins 0.000 claims description 6
- 230000006735 deficit Effects 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000007794 irritation Effects 0.000 claims description 6
- 230000028327 secretion Effects 0.000 claims description 5
- 238000010254 subcutaneous injection Methods 0.000 claims description 5
- 239000007929 subcutaneous injection Substances 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- 239000013043 chemical agent Substances 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 230000000622 irritating effect Effects 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 3
- 102000008070 Interferon-gamma Human genes 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 239000013566 allergen Substances 0.000 claims description 3
- 229940044627 gamma-interferon Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 108091081021 Sense strand Proteins 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 82
- 239000013598 vector Substances 0.000 abstract description 32
- 239000002502 liposome Substances 0.000 abstract description 21
- 238000002360 preparation method Methods 0.000 abstract description 11
- 238000011161 development Methods 0.000 abstract description 5
- 238000002255 vaccination Methods 0.000 abstract description 3
- 208000035240 Disease Resistance Diseases 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 134
- 241000699670 Mus sp. Species 0.000 description 122
- 239000013612 plasmid Substances 0.000 description 89
- 239000007924 injection Substances 0.000 description 77
- 238000002347 injection Methods 0.000 description 76
- 210000004027 cell Anatomy 0.000 description 70
- 102000004169 proteins and genes Human genes 0.000 description 56
- 241001465754 Metazoa Species 0.000 description 37
- 108020004635 Complementary DNA Proteins 0.000 description 34
- 238000002965 ELISA Methods 0.000 description 32
- 238000010804 cDNA synthesis Methods 0.000 description 32
- 230000000694 effects Effects 0.000 description 30
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 25
- 238000002560 therapeutic procedure Methods 0.000 description 24
- 239000003618 borate buffered saline Substances 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 210000003205 muscle Anatomy 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 21
- 241000714474 Rous sarcoma virus Species 0.000 description 20
- 239000007927 intramuscular injection Substances 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 238000003556 assay Methods 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 238000010255 intramuscular injection Methods 0.000 description 17
- 108020004999 messenger RNA Proteins 0.000 description 17
- 238000013459 approach Methods 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 239000013604 expression vector Substances 0.000 description 13
- 239000012581 transferrin Substances 0.000 description 13
- 102000000589 Interleukin-1 Human genes 0.000 description 12
- 108010002352 Interleukin-1 Proteins 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 11
- 102000053642 Catalytic RNA Human genes 0.000 description 10
- 108090000994 Catalytic RNA Proteins 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 108091092562 ribozyme Proteins 0.000 description 10
- 102000053602 DNA Human genes 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 102000004338 Transferrin Human genes 0.000 description 9
- 108090000901 Transferrin Proteins 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 210000005087 mononuclear cell Anatomy 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 108010058846 Ovalbumin Proteins 0.000 description 8
- 230000005875 antibody response Effects 0.000 description 8
- 102000005936 beta-Galactosidase Human genes 0.000 description 8
- 108010005774 beta-Galactosidase Proteins 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- 238000012377 drug delivery Methods 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 229940092253 ovalbumin Drugs 0.000 description 8
- 230000002035 prolonged effect Effects 0.000 description 8
- 230000001177 retroviral effect Effects 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 206010025323 Lymphomas Diseases 0.000 description 7
- 108010081734 Ribonucleoproteins Proteins 0.000 description 7
- 230000002500 effect on skin Effects 0.000 description 7
- 150000007523 nucleic acids Chemical group 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 239000013600 plasmid vector Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 230000005951 type IV hypersensitivity Effects 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 210000000663 muscle cell Anatomy 0.000 description 6
- 210000000822 natural killer cell Anatomy 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 229920000136 polysorbate Polymers 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 230000003442 weekly effect Effects 0.000 description 6
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 5
- 102000004389 Ribonucleoproteins Human genes 0.000 description 5
- 102000009618 Transforming Growth Factors Human genes 0.000 description 5
- 108010009583 Transforming Growth Factors Proteins 0.000 description 5
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 5
- 239000000074 antisense oligonucleotide Substances 0.000 description 5
- 238000012230 antisense oligonucleotides Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 210000002683 foot Anatomy 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 239000000122 growth hormone Substances 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 206010022000 influenza Diseases 0.000 description 5
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000004681 ovum Anatomy 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000006748 scratching Methods 0.000 description 5
- 230000002393 scratching effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000008733 trauma Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 201000000628 Gas Gangrene Diseases 0.000 description 4
- 108010051696 Growth Hormone Proteins 0.000 description 4
- 102000018997 Growth Hormone Human genes 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 102000011931 Nucleoproteins Human genes 0.000 description 4
- 108010061100 Nucleoproteins Proteins 0.000 description 4
- 102000013275 Somatomedins Human genes 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000001926 lymphatic effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 206010028320 muscle necrosis Diseases 0.000 description 4
- GSSMIHQEWAQUPM-AOLPDKKJSA-N ovalbumin peptide Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CN=CN1 GSSMIHQEWAQUPM-AOLPDKKJSA-N 0.000 description 4
- 235000020030 perry Nutrition 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 241000713869 Moloney murine leukemia virus Species 0.000 description 3
- 101150118742 NP gene Proteins 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 241000555745 Sciuridae Species 0.000 description 3
- 208000019802 Sexually transmitted disease Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000008512 biological response Effects 0.000 description 3
- 238000001246 colloidal dispersion Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000001461 cytolytic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 210000004392 genitalia Anatomy 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 238000009256 replacement therapy Methods 0.000 description 3
- 230000003938 response to stress Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241001559589 Cullen Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 241000713858 Harvey murine sarcoma virus Species 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108700020978 Proto-Oncogene Proteins 0.000 description 2
- 102000052575 Proto-Oncogene Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 241000251131 Sphyrna Species 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000961 alloantigen Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000002951 depilatory effect Effects 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000008241 heterogeneous mixture Substances 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 230000006054 immunological memory Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000012153 long-term therapy Methods 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 201000006512 mast cell neoplasm Diseases 0.000 description 2
- 208000006971 mastocytoma Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000013271 transdermal drug delivery Methods 0.000 description 2
- 229960001005 tuberculin Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000714235 Avian retrovirus Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 101150088952 IGF1 gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101150038444 Ment gene Proteins 0.000 description 1
- 101001043827 Mus musculus Interleukin-2 Proteins 0.000 description 1
- 101001002703 Mus musculus Interleukin-4 Proteins 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 208000030303 breathing problems Diseases 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000816 effect on animals Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000000066 endothelium dependent relaxing factor Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000001911 interdigitating cell Anatomy 0.000 description 1
- 230000018276 interleukin-1 production Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100001106 life-threatening toxicity Toxicity 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007108 local immune response Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 108010030416 proteoliposomes Proteins 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000009677 vaginal delivery Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000005135 veiled cell Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 210000001260 vocal cord Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/20—Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/20—Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
- A61B17/205—Vaccinating by means of needles or other puncturing devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/77—Ovalbumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU76391/94A AU705889B2 (en) | 1993-08-26 | 1994-08-25 | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory peptides |
US08/464,878 US5830877A (en) | 1993-08-26 | 1994-08-25 | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory |
JP7507766A JPH09501936A (en) | 1993-08-26 | 1994-08-25 | Methods, Compositions and Devices for Administering Naked Polynucleotides Encoding Bioactive Peptides |
EP94926603A EP0714308A4 (en) | 1993-08-26 | 1994-08-25 | Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides |
CA002169635A CA2169635C (en) | 1993-08-26 | 1994-08-25 | Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides |
US08/333,068 US5804566A (en) | 1993-08-26 | 1994-11-01 | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
US08/334,260 US5679647A (en) | 1993-08-26 | 1994-11-03 | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
US08/725,968 US5849719A (en) | 1993-08-26 | 1996-10-04 | Method for treating allergic lung disease |
US08/928,412 US5985847A (en) | 1993-08-26 | 1997-09-12 | Devices for administration of naked polynucleotides which encode biologically active peptides |
US10/402,100 US20030186921A1 (en) | 1993-08-26 | 2003-03-26 | Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11244093A | 1993-08-26 | 1993-08-26 | |
US08/112,440 | 1993-08-26 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11244093A Continuation-In-Part | 1993-08-26 | 1993-08-26 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US44669195A Division | 1993-08-26 | 1995-06-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1995005853A1 true WO1995005853A1 (en) | 1995-03-02 |
WO1995005853A9 WO1995005853A9 (en) | 1996-04-25 |
Family
ID=22343912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/009661 WO1995005853A1 (en) | 1993-08-26 | 1994-08-25 | Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0714308A4 (en) |
JP (2) | JPH09501936A (en) |
AU (1) | AU705889B2 (en) |
CA (1) | CA2169635C (en) |
MX (1) | MX9406552A (en) |
WO (1) | WO1995005853A1 (en) |
Cited By (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996029410A1 (en) * | 1995-03-22 | 1996-09-26 | Zeneca Limited | In vivo generation of antibodies against antigens secreted in a host by transfected mel cells |
WO1996030521A2 (en) * | 1995-03-31 | 1996-10-03 | Immuno Aktiengesellschaft | Infectious dna clone of the tick-borne encephalitis (tbe) virus; recombinant vaccine derived from the said clone and production of the said vaccine; and a pharmaceutical product containing a replicable nucleic acid |
WO1997024447A1 (en) * | 1996-01-02 | 1997-07-10 | Chiron Corporation | Immunostimulation mediated by gene-modified dendritic cells |
WO1997028818A1 (en) * | 1996-02-12 | 1997-08-14 | Cobra Therapeutics Limited | Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope |
WO1997032987A1 (en) * | 1996-03-08 | 1997-09-12 | University Of Toronto | Methods and nucleic immunogenic compositions encoding antigens and co-stimulatory molecules for immunization |
EP0794797A1 (en) * | 1994-11-01 | 1997-09-17 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides which encode antigenic peptides |
US5703057A (en) * | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
WO1998008947A1 (en) * | 1995-12-19 | 1998-03-05 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Enhancement of dna immunization through the use of cytokines |
WO1998014210A1 (en) * | 1996-10-04 | 1998-04-09 | The Regents Of The University Of California | Method for treating allergic lung disease |
EP0855184A1 (en) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
WO1998045408A2 (en) * | 1996-04-10 | 1998-10-15 | Heska Corporation | Novel ectoparasite saliva proteins and apparatus to collect such proteins |
WO1999036563A1 (en) * | 1998-01-14 | 1999-07-22 | Emed Corporation | Electrically mediated cellular expression |
US5958891A (en) * | 1996-04-24 | 1999-09-28 | Hsu; Ching-Hsiang | Recombinant eukaryotic plasmids containing allergen-gene and use thereof for the prevention and/or treatment of allergic diseases |
WO1999039741A3 (en) * | 1998-02-03 | 1999-09-30 | Inex Pharmaceuticals Corp | Systemic delivery of serum stable plasmid lipid particles for cancer therapy |
US6194389B1 (en) * | 1989-11-16 | 2001-02-27 | Duke University | Particle-mediated bombardment of DNA sequences into tissue to induce an immune response |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6214806B1 (en) | 1997-02-28 | 2001-04-10 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders |
US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6270795B1 (en) | 1995-11-09 | 2001-08-07 | Microbiological Research Authority | Method of making microencapsulated DNA for vaccination and gene therapy |
US6309569B1 (en) | 1998-05-13 | 2001-10-30 | Microbiological Research Authority | Encapsulation of bioactive agents |
US6339068B1 (en) | 1997-05-20 | 2002-01-15 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
US6348450B1 (en) | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6406719B1 (en) | 1998-05-13 | 2002-06-18 | Microbiological Research Authority | Encapsulation of bioactive agents |
WO2002055559A1 (en) * | 2001-01-15 | 2002-07-18 | Keryos Spa | Dna vaccines expressing hypervariable vh-cdr3 idiotipic determinants |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6498148B1 (en) | 1997-09-05 | 2002-12-24 | The Regents Of The University Of California | Immunization-free methods for treating antigen-stimulated inflammation in a mammalian host and shifting the host's antigen immune responsiveness to a Th1 phenotype |
US6610661B1 (en) | 1996-10-11 | 2003-08-26 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
US6635624B1 (en) | 1993-10-22 | 2003-10-21 | Institut Pasteur | Nucleotide vector composition containing such vector and vaccine for immunization against hepatitis |
US6667294B2 (en) | 1995-11-09 | 2003-12-23 | Microbiological Research Authority | Microencapsulated DNA for vaccination and gene therapy |
US6689757B1 (en) | 1996-02-12 | 2004-02-10 | M.L. Laboratories Plc | Methods for vaccination and vaccines therefor |
US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
US6727230B1 (en) | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US6787138B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
US6808712B2 (en) | 1997-12-02 | 2004-10-26 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6878813B2 (en) | 1998-05-12 | 2005-04-12 | Temple University - Of The Commonwealth System Of Higher Education | Human antithrombin IIIs and methods related thereto |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
WO2006020581A2 (en) | 2004-08-09 | 2006-02-23 | Elan Pharmaceuticals, Inc. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
WO2006079014A2 (en) * | 2005-01-21 | 2006-07-27 | Introgen Therapeutics, Inc. | Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids |
US7166693B2 (en) | 1995-10-06 | 2007-01-23 | Heska Corporation | Ectoparasite saliva proteins |
WO2008042024A2 (en) | 2006-06-01 | 2008-04-10 | Elan Pharmaceuticals, Inc. | Neuroactive fragments of app |
US7482139B2 (en) | 2002-05-31 | 2009-01-27 | University Of Utah Research Foundation | Variants of antithrombin III |
EP2042599A1 (en) | 1997-05-15 | 2009-04-01 | Health Protection Agency | Method of making microencapsulated DNA for vaccination and gene therapy |
EP2045267A2 (en) | 2000-12-06 | 2009-04-08 | Elan Pharma International Limited | Humanized antibodies that recognize beta amyloid peptide |
WO2009046407A2 (en) | 2007-10-04 | 2009-04-09 | Zymogenetics, Inc. | B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS |
WO2009078799A1 (en) | 2007-12-17 | 2009-06-25 | Marfl Ab | New vaccine for the treatment of mycobacterium related disorders |
WO2009086539A2 (en) | 2007-12-28 | 2009-07-09 | Elan Pharmaceuticals, Inc. | Treatment and prophylaxis of amyloidosis |
US7628990B2 (en) | 1999-11-15 | 2009-12-08 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
US7666495B2 (en) | 2002-08-24 | 2010-02-23 | International Paper Company | Uncoated facestock for adhesive-backed labels |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
US7776321B2 (en) | 2001-09-26 | 2010-08-17 | Mayo Foundation For Medical Education And Research | Mutable vaccines |
EP2221064A1 (en) | 2003-03-12 | 2010-08-25 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US7871615B2 (en) | 2003-05-30 | 2011-01-18 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US7893214B2 (en) | 1997-12-02 | 2011-02-22 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
EP2305302A2 (en) | 1999-05-28 | 2011-04-06 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidogenic disease |
US7977316B2 (en) | 1999-06-01 | 2011-07-12 | Elan Pharmaceuticals, Inc. | Prevention and treatment of amyloidogenic diseases |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
EP2361629A1 (en) | 2002-11-01 | 2011-08-31 | Elan Pharmaceuticals Inc. | Prevention and treatment of synucleinopathic disease |
US8062842B2 (en) | 2004-02-24 | 2011-11-22 | Abbott Healthcare Products B.V. | Method for determining the risk of developing a neurological disease |
WO2011156356A1 (en) | 2010-06-09 | 2011-12-15 | Zymogenetics, Inc. | Dimeric vstm3 fusion proteins and related compositions and methods |
US8105594B2 (en) | 1998-05-21 | 2012-01-31 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US8128928B2 (en) | 2002-03-12 | 2012-03-06 | Wyeth Llc | Humanized antibodies that recognize beta amyloid peptide |
EP2450056A1 (en) | 2005-07-19 | 2012-05-09 | Elan Pharma International Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
WO2013041962A1 (en) | 2011-09-19 | 2013-03-28 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
EP2583978A2 (en) | 2007-02-23 | 2013-04-24 | The Regents of the University of California | Prevention and treatment of synucleinopathic and amyloidogenic disease |
EP2650014A2 (en) | 2008-06-20 | 2013-10-16 | Wyeth LLC | Compositions and methods of use of ORF1358 from beta-hemolytic streptococcal strains |
US8613920B2 (en) | 2007-07-27 | 2013-12-24 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US8647864B2 (en) | 1999-04-14 | 2014-02-11 | Novartis Ag | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
USRE45196E1 (en) | 2005-03-04 | 2014-10-14 | Dynavax Technologies Corporation | Compositions comprising structurally stable conjugate molecules |
US8916165B2 (en) | 2004-12-15 | 2014-12-23 | Janssen Alzheimer Immunotherapy | Humanized Aβ antibodies for use in improving cognition |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
EP3067066A1 (en) | 2007-02-23 | 2016-09-14 | Prothena Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US9512489B2 (en) | 2012-05-10 | 2016-12-06 | Korea Hydro & Nuclear Power Co., Ltd. | Method for detecting genes sensitive to low-level ionizing radiation |
US9644025B2 (en) | 2007-10-17 | 2017-05-09 | Wyeth Llc | Immunotherapy regimes dependent on ApoE status |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE421888T1 (en) * | 1997-08-13 | 2009-02-15 | Uab Research Foundation | VACCINATION BY TOPICAL USE OF GENETIC VECTORS |
WO1999053912A1 (en) * | 1998-04-20 | 1999-10-28 | Torrey Pines Institute For Molecular Studies | Topical immunostimulation to induce langerhans cell migration |
DE60007290T2 (en) * | 1999-01-28 | 2004-09-23 | Cyto Pulse Sciences, Inc. | INTRODUCTION OF MACROMOLECULES IN CELLS |
US6335182B1 (en) * | 1999-03-16 | 2002-01-01 | Aventis Pasteur Limited | Recombinant Haemophilus influenzae adhesin proteins |
GB0201736D0 (en) * | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | DNA dosage forms |
CA2742049A1 (en) * | 2008-10-31 | 2010-05-06 | The Brigham And Women's Hospital, Inc. | Vaccination with poxvirus vectors via mechanical epidermal disruption |
JP5917626B2 (en) * | 2014-07-28 | 2016-05-18 | トレムアールエックス, インコーポレイテッド | Vaccination with poxvirus vectors via mechanical epidermal destruction |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3596660A (en) * | 1969-05-12 | 1971-08-03 | Illinois Tool Works | Injection device |
AU570998B2 (en) * | 1983-09-07 | 1988-03-31 | Takeda Chemical Industries Ltd. | Topical steroid compositions for acne |
CA2489769A1 (en) * | 1989-03-21 | 1990-10-04 | Philip L. Felgner | Expression of exogenous polynucleotide sequences in a vertebrate |
US5157020A (en) * | 1990-05-24 | 1992-10-20 | Research Corporation Tech., Inc. | Synthetic senescent cell antigen |
NZ239274A (en) * | 1991-08-05 | 1995-12-21 | Zenith Technology Corp Ltd | Scratch fluid medicament applicator for applying a vaccine to an animal |
ATE302854T1 (en) * | 1993-01-26 | 2005-09-15 | Univ Pennsylvania | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF GENETIC MATERIAL |
-
1994
- 1994-08-25 EP EP94926603A patent/EP0714308A4/en not_active Withdrawn
- 1994-08-25 AU AU76391/94A patent/AU705889B2/en not_active Ceased
- 1994-08-25 JP JP7507766A patent/JPH09501936A/en not_active Ceased
- 1994-08-25 WO PCT/US1994/009661 patent/WO1995005853A1/en active Application Filing
- 1994-08-25 CA CA002169635A patent/CA2169635C/en not_active Expired - Fee Related
- 1994-08-26 MX MX9406552A patent/MX9406552A/en not_active IP Right Cessation
-
2004
- 2004-06-07 JP JP2004168972A patent/JP2004331668A/en active Pending
Non-Patent Citations (5)
Title |
---|
MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, issued 16-20 September 1992, ROBINSON et al.: "Use of direct DNA inoculations to elicit protective immune responses", page 92, entire abstract. * |
SCIENCE, Volume 259, issued 19 March 1993, J. COHEN: "Naked DNA points the way to vaccines", pages 1691-1692, entire document. * |
SCIENCE, Volume 259, issued 19 March 1993, J.B. ULMER et al.: "Heterologous protection against influenza by injection of DNA encoding a viral protein", pages 1745-1749, entire document. * |
See also references of EP0714308A4 * |
THE NEW YORK TIMES, issued 30 March 1993, R.M. HENIG: "New vaccine method using DNA protects mice against a flu virus", pages B8 and B9, entire document. * |
Cited By (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7449449B2 (en) | 1989-11-16 | 2008-11-11 | Duke University | Particle-mediated transformation of vertebrate tissue cells |
US6194389B1 (en) * | 1989-11-16 | 2001-02-27 | Duke University | Particle-mediated bombardment of DNA sequences into tissue to induce an immune response |
US7358234B2 (en) | 1989-11-16 | 2008-04-15 | Duke University | Induction of a protective immune response through microprojectiles coated with a DNA sequence encoding an immunogenic protein |
US7825097B2 (en) | 1993-10-22 | 2010-11-02 | Institut Pasteur | Nucleotide vector vaccine for immunization against hepatitis |
US6635624B1 (en) | 1993-10-22 | 2003-10-21 | Institut Pasteur | Nucleotide vector composition containing such vector and vaccine for immunization against hepatitis |
US6727230B1 (en) | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US7888327B2 (en) | 1994-07-15 | 2011-02-15 | University Of Iowa Research Foundation | Methods of using immunostimulatory nucleic acid molecules to treat allergic conditions |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6653292B1 (en) | 1994-07-15 | 2003-11-25 | University Of Iowa Research Foundation | Method of treating cancer using immunostimulatory oligonucleotides |
US7629446B2 (en) | 1994-10-07 | 2009-12-08 | Heska Corporation | Nucleic acid molecules encoding a novel ectoparasite saliva protein |
EP0794797A4 (en) * | 1994-11-01 | 2001-09-05 | Univ California | Methods and devices for immunizing a host through administration of naked polynucleotides which encode antigenic peptides |
EP0794797A1 (en) * | 1994-11-01 | 1997-09-17 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides which encode antigenic peptides |
WO1996029410A1 (en) * | 1995-03-22 | 1996-09-26 | Zeneca Limited | In vivo generation of antibodies against antigens secreted in a host by transfected mel cells |
WO1996030521A2 (en) * | 1995-03-31 | 1996-10-03 | Immuno Aktiengesellschaft | Infectious dna clone of the tick-borne encephalitis (tbe) virus; recombinant vaccine derived from the said clone and production of the said vaccine; and a pharmaceutical product containing a replicable nucleic acid |
WO1996030521A3 (en) * | 1995-03-31 | 2001-09-13 | Immuno Ag | Infectious dna clone of the tick-borne encephalitis (tbe) virus; recombinant vaccine derived from the said clone and production of the said vaccine; and a pharmaceutical product containing a replicable nucleic acid |
US5989553A (en) * | 1995-04-07 | 1999-11-23 | Board Of Regents, The University Of Texas System | Expression library immunization |
US5703057A (en) * | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
US7166693B2 (en) | 1995-10-06 | 2007-01-23 | Heska Corporation | Ectoparasite saliva proteins |
US6667294B2 (en) | 1995-11-09 | 2003-12-23 | Microbiological Research Authority | Microencapsulated DNA for vaccination and gene therapy |
US6270795B1 (en) | 1995-11-09 | 2001-08-07 | Microbiological Research Authority | Method of making microencapsulated DNA for vaccination and gene therapy |
WO1998008947A1 (en) * | 1995-12-19 | 1998-03-05 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Enhancement of dna immunization through the use of cytokines |
WO1997024447A1 (en) * | 1996-01-02 | 1997-07-10 | Chiron Corporation | Immunostimulation mediated by gene-modified dendritic cells |
WO1997028818A1 (en) * | 1996-02-12 | 1997-08-14 | Cobra Therapeutics Limited | Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope |
AU724716B2 (en) * | 1996-02-12 | 2000-09-28 | Ml Laboratories Plc | Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope |
US6689757B1 (en) | 1996-02-12 | 2004-02-10 | M.L. Laboratories Plc | Methods for vaccination and vaccines therefor |
WO1997032987A1 (en) * | 1996-03-08 | 1997-09-12 | University Of Toronto | Methods and nucleic immunogenic compositions encoding antigens and co-stimulatory molecules for immunization |
WO1998045408A3 (en) * | 1996-04-10 | 1999-01-07 | Heska Corp | Novel ectoparasite saliva proteins and apparatus to collect such proteins |
WO1998045408A2 (en) * | 1996-04-10 | 1998-10-15 | Heska Corporation | Novel ectoparasite saliva proteins and apparatus to collect such proteins |
US6251663B1 (en) | 1996-04-24 | 2001-06-26 | Jen Wen Co., Ltd. | Recombinant eukaryotic plasmids containing allergen-gene and use thereof for the prevention and/or treatment of allergic diseases |
US5958891A (en) * | 1996-04-24 | 1999-09-28 | Hsu; Ching-Hsiang | Recombinant eukaryotic plasmids containing allergen-gene and use thereof for the prevention and/or treatment of allergic diseases |
US6174872B1 (en) | 1996-10-04 | 2001-01-16 | The Regents Of The University Of California | Method for treating allergic lung disease |
US6426336B1 (en) | 1996-10-04 | 2002-07-30 | The Regents Of The University Of California | Method for treating allergic lung disease |
WO1998014210A1 (en) * | 1996-10-04 | 1998-04-09 | The Regents Of The University Of California | Method for treating allergic lung disease |
AU740600B2 (en) * | 1996-10-04 | 2001-11-08 | Regents Of The University Of California, The | Method for treating allergic lung disease |
US7208478B2 (en) | 1996-10-11 | 2007-04-24 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
US6610661B1 (en) | 1996-10-11 | 2003-08-26 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
EP0855184A1 (en) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
US7001890B1 (en) | 1997-01-23 | 2006-02-21 | Coley Pharmaceutical Gmbh | Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination |
WO1998032462A1 (en) * | 1997-01-23 | 1998-07-30 | Hermann Wagner | Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination |
US6214806B1 (en) | 1997-02-28 | 2001-04-10 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
EP2042599A1 (en) | 1997-05-15 | 2009-04-01 | Health Protection Agency | Method of making microencapsulated DNA for vaccination and gene therapy |
US6821957B2 (en) | 1997-05-20 | 2004-11-23 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
US6339068B1 (en) | 1997-05-20 | 2002-01-15 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
US6348450B1 (en) | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
US6498148B1 (en) | 1997-09-05 | 2002-12-24 | The Regents Of The University Of California | Immunization-free methods for treating antigen-stimulated inflammation in a mammalian host and shifting the host's antigen immune responsiveness to a Th1 phenotype |
US8034339B2 (en) | 1997-12-02 | 2011-10-11 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidogenic disease |
US8535673B2 (en) | 1997-12-02 | 2013-09-17 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidogenic disease |
US9051363B2 (en) | 1997-12-02 | 2015-06-09 | Janssen Sciences Ireland Uc | Humanized antibodies that recognize beta amyloid peptide |
US6787140B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6787143B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6787144B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6808712B2 (en) | 1997-12-02 | 2004-10-26 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6818218B2 (en) | 1997-12-02 | 2004-11-16 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6787138B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US7893214B2 (en) | 1997-12-02 | 2011-02-22 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US6787139B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6982084B2 (en) | 1997-12-02 | 2006-01-03 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US8642044B2 (en) | 1997-12-02 | 2014-02-04 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidogenic disease |
EP1994937A2 (en) | 1997-12-02 | 2008-11-26 | Elan Pharma International Limited | Prevention and treatment of amyloidogenic disease |
EP2305282A2 (en) | 1997-12-02 | 2011-04-06 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidogenic disease |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
US8034348B2 (en) | 1997-12-02 | 2011-10-11 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidogenic disease |
WO1999036563A1 (en) * | 1998-01-14 | 1999-07-22 | Emed Corporation | Electrically mediated cellular expression |
WO1999039741A3 (en) * | 1998-02-03 | 1999-09-30 | Inex Pharmaceuticals Corp | Systemic delivery of serum stable plasmid lipid particles for cancer therapy |
US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US6878813B2 (en) | 1998-05-12 | 2005-04-12 | Temple University - Of The Commonwealth System Of Higher Education | Human antithrombin IIIs and methods related thereto |
US6565777B2 (en) | 1998-05-13 | 2003-05-20 | Microbiological Research Authority | Encapsulation of bioactive agents |
US6309569B1 (en) | 1998-05-13 | 2001-10-30 | Microbiological Research Authority | Encapsulation of bioactive agents |
US6406719B1 (en) | 1998-05-13 | 2002-06-18 | Microbiological Research Authority | Encapsulation of bioactive agents |
US8105594B2 (en) | 1998-05-21 | 2012-01-31 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US8647864B2 (en) | 1999-04-14 | 2014-02-11 | Novartis Ag | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
EP2305302A2 (en) | 1999-05-28 | 2011-04-06 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidogenic disease |
EP2364719A1 (en) | 1999-06-01 | 2011-09-14 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidogenic diseases |
US7977316B2 (en) | 1999-06-01 | 2011-07-12 | Elan Pharmaceuticals, Inc. | Prevention and treatment of amyloidogenic diseases |
US8124081B2 (en) | 1999-06-01 | 2012-02-28 | Crimagua Limited | Prevention and treatment of amyloidogenic diseases |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
US7776344B2 (en) | 1999-09-27 | 2010-08-17 | University Of Iowa Research Foundation | Methods related to immunostimulatory nucleic acid-induced interferon |
US7628990B2 (en) | 1999-11-15 | 2009-12-08 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
EP2045267A2 (en) | 2000-12-06 | 2009-04-08 | Elan Pharma International Limited | Humanized antibodies that recognize beta amyloid peptide |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
WO2002055559A1 (en) * | 2001-01-15 | 2002-07-18 | Keryos Spa | Dna vaccines expressing hypervariable vh-cdr3 idiotipic determinants |
US7354759B2 (en) | 2001-01-15 | 2008-04-08 | Keryos Spa | DNA vaccines expressing hypervariable VH-CDR3 idiotypic determinants |
US7776321B2 (en) | 2001-09-26 | 2010-08-17 | Mayo Foundation For Medical Education And Research | Mutable vaccines |
US8128928B2 (en) | 2002-03-12 | 2012-03-06 | Wyeth Llc | Humanized antibodies that recognize beta amyloid peptide |
US7482139B2 (en) | 2002-05-31 | 2009-01-27 | University Of Utah Research Foundation | Variants of antithrombin III |
US7666495B2 (en) | 2002-08-24 | 2010-02-23 | International Paper Company | Uncoated facestock for adhesive-backed labels |
EP2361629A1 (en) | 2002-11-01 | 2011-08-31 | Elan Pharmaceuticals Inc. | Prevention and treatment of synucleinopathic disease |
EP2221064A1 (en) | 2003-03-12 | 2010-08-25 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US7871615B2 (en) | 2003-05-30 | 2011-01-18 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US8062842B2 (en) | 2004-02-24 | 2011-11-22 | Abbott Healthcare Products B.V. | Method for determining the risk of developing a neurological disease |
EP3369433A1 (en) | 2004-08-09 | 2018-09-05 | Janssen Alzheimer Immunotherapy | Prevention and treatment of synucleinopathic and amyloidogenic disease |
WO2006020581A2 (en) | 2004-08-09 | 2006-02-23 | Elan Pharmaceuticals, Inc. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US8916165B2 (en) | 2004-12-15 | 2014-12-23 | Janssen Alzheimer Immunotherapy | Humanized Aβ antibodies for use in improving cognition |
WO2006079014A2 (en) * | 2005-01-21 | 2006-07-27 | Introgen Therapeutics, Inc. | Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids |
WO2006079014A3 (en) * | 2005-01-21 | 2006-11-09 | Introgen Therapeutics Inc | Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids |
USRE45196E1 (en) | 2005-03-04 | 2014-10-14 | Dynavax Technologies Corporation | Compositions comprising structurally stable conjugate molecules |
EP2450056A1 (en) | 2005-07-19 | 2012-05-09 | Elan Pharma International Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
WO2008042024A2 (en) | 2006-06-01 | 2008-04-10 | Elan Pharmaceuticals, Inc. | Neuroactive fragments of app |
EP3067066A1 (en) | 2007-02-23 | 2016-09-14 | Prothena Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
EP2583978A2 (en) | 2007-02-23 | 2013-04-24 | The Regents of the University of California | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
US8613920B2 (en) | 2007-07-27 | 2013-12-24 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
EP3241846A1 (en) | 2007-10-04 | 2017-11-08 | ZymoGenetics, Inc. | B7 family member zb7h6 and related compositions and methods |
WO2009046407A2 (en) | 2007-10-04 | 2009-04-09 | Zymogenetics, Inc. | B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS |
US9644025B2 (en) | 2007-10-17 | 2017-05-09 | Wyeth Llc | Immunotherapy regimes dependent on ApoE status |
US8779088B2 (en) | 2007-12-17 | 2014-07-15 | Marfl Ab | Vaccine for the treatment of Mycobacterium related disorders |
WO2009078799A1 (en) | 2007-12-17 | 2009-06-25 | Marfl Ab | New vaccine for the treatment of mycobacterium related disorders |
EP2730659A2 (en) | 2007-12-28 | 2014-05-14 | Elan Pharmaceuticals Inc. | Treatment and Prophylaxis of Amyloidosis |
WO2009086539A2 (en) | 2007-12-28 | 2009-07-09 | Elan Pharmaceuticals, Inc. | Treatment and prophylaxis of amyloidosis |
EP3693470A1 (en) | 2007-12-28 | 2020-08-12 | Prothena Therapeutics Limited | Treatment and prophylaxis of amyloidosis |
EP2650014A2 (en) | 2008-06-20 | 2013-10-16 | Wyeth LLC | Compositions and methods of use of ORF1358 from beta-hemolytic streptococcal strains |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
US8822642B2 (en) | 2010-06-09 | 2014-09-02 | Zymogenetics, Inc. | Dimeric fusion proteins and related compositions and methods |
WO2011156356A1 (en) | 2010-06-09 | 2011-12-15 | Zymogenetics, Inc. | Dimeric vstm3 fusion proteins and related compositions and methods |
WO2013041962A1 (en) | 2011-09-19 | 2013-03-28 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
EP3275461A1 (en) | 2011-09-19 | 2018-01-31 | Axon Neuroscience SE | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field |
US9708668B2 (en) | 2012-05-10 | 2017-07-18 | Korea Hydro & Nuclear Power Co., Ltd. | Method for detecting genes sensitive to low-level ionizing radiation |
US9714453B2 (en) | 2012-05-10 | 2017-07-25 | Korea Hydro & Nuclear Power Co., Ltd. | Method for detecting genes sensitive to low-level ionizing radiation |
US9708670B2 (en) | 2012-05-10 | 2017-07-18 | Korea Hydro & Nuclear Power Co., Ltd. | Method for detecting genes sensitive to low-level ionizing radiation |
US9708669B2 (en) | 2012-05-10 | 2017-07-18 | Korea Hydro & Nuclear Power Co., Ltd. | Method for detecting genes sensitive to low-level ionizing radiation |
US9512489B2 (en) | 2012-05-10 | 2016-12-06 | Korea Hydro & Nuclear Power Co., Ltd. | Method for detecting genes sensitive to low-level ionizing radiation |
Also Published As
Publication number | Publication date |
---|---|
EP0714308A4 (en) | 1998-07-29 |
EP0714308A1 (en) | 1996-06-05 |
CA2169635C (en) | 2002-11-12 |
AU705889B2 (en) | 1999-06-03 |
JP2004331668A (en) | 2004-11-25 |
CA2169635A1 (en) | 1995-03-02 |
JPH09501936A (en) | 1997-02-25 |
MX9406552A (en) | 1997-02-28 |
AU7639194A (en) | 1995-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5830877A (en) | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory | |
US5985847A (en) | Devices for administration of naked polynucleotides which encode biologically active peptides | |
AU705889B2 (en) | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory peptides | |
WO1995005853A9 (en) | Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides | |
CA2204253C (en) | Methods and devices for immunizing a host through administration of naked polynucleotides which encode antigenic peptides | |
CA2244946C (en) | Gene expression vectors which generate an antigen specific immune response and methods of using the same | |
US5679647A (en) | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides | |
US5849719A (en) | Method for treating allergic lung disease | |
US20030109469A1 (en) | Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen | |
JP2002500159A (en) | Use of immunostimulatory oligonucleotides to prevent or reduce antigen-stimulated granulocyte-mediated inflammation | |
JP2011502163A (en) | Combination therapies to treat persistent viral infections | |
US20040191761A1 (en) | Modified adenoviral E1A constructs and methods of use thereof | |
AU759590B2 (en) | Gene expression vectors which generate an antigen specific immune response and methods of using the same | |
AU1841897A (en) | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 08333068 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08334260 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 1995 446691 Country of ref document: US Date of ref document: 19950607 Kind code of ref document: A |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 08464878 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2169635 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994926603 Country of ref document: EP |
|
COP | Corrected version of pamphlet |
Free format text: PAGE 87,AMENDED CLAIMS,REPLACED BY CORRECT PAGE 87 |
|
WWP | Wipo information: published in national office |
Ref document number: 1994926603 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |